MGC Pharmaceuticals

MGC Pharmaceuticals

Global next-generation Pharma licensed company. Improving lives with innovative plant-inspired medicine.

Founded 2005

London, United Kingdom 37 employees Post-IPO Equity Total: $20.70M Pharmaceutical, Wellness Beauty

MGC Pharmaceuticals is a next-generation Pharma licensed company that is revolutionizing the global plant-inspired pharmaceutical market. With headquarters in the United Kingdom, production centers in Slovenia and Malta, and research centers in Slovenia and Israel, the company stands at the forefront of research, production, and sales of innovative plant-inspired medications. MGC has successfully developed an efficient production pipeline, with three clinical arms in Neurology, Oncology, and Autoimmune. The company's goal is to provide "Cost Effective, Standardized, Affordable Medicines" and has established a full EU-GMP certified facility in Slovenia and Malta. MGC Pharmaceuticals has been making notable strides in the pharmaceutical and wellness beauty industries since its establishment in 2005. The company's commitment to quality and innovation is evident in its flagship products, including CannEpil™, CogniCann™, and Cimetra™, which are in the late stage of clinical development. With other products such as IrniCann for Glioblastoma, InCann for Crohn’s disease and colitis, and TopiCann for anti-inflammatory purposes following closely behind, MGC Pharmaceuticals continues to demonstrate a promising pipeline of pharmaceutical advancements. The company's recent £50.00KPost-IPO Debt investment at 14 July 2023 by Roby Zomer further solidifies its position in the market and signals confidence in its ongoing initiatives. MGC Pharmaceuticals' commitment to improving lives with innovative plant-inspired medicine is encapsulated in its mission and has positioned the company as a significant player in the global pharmaceutical landscape.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	£650.00K	-		14 Jul 2023
Post IPO Debt	£50.00K	1	Roby Zomer	14 Jul 2023
Grant	$5.00M	1	Malta Enterprise	22 Dec 2020
Post IPO Equity	$5.00M	-		12 Apr 2018
Post IPO Equity	$10.00M	-		17 Mar 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

£650.00K

14 Jul 2023

Post IPO Debt

£50.00K

Roby Zomer

14 Jul 2023

Grant

$5.00M

Malta Enterprise

22 Dec 2020

Post IPO Equity

$5.00M

12 Apr 2018

Post IPO Equity

$10.00M

17 Mar 2017

FAQ About MGC Pharmaceuticals

Global next-generation Pharma licensed company. Improving lives with innovative plant-inspired medicine.

MGC Pharmaceuticals was founded in 2005.

MGC Pharmaceuticals is headquartered in London, United Kingdom.

MGC Pharmaceuticals operates in Pharmaceutical and Wellness Beauty. Its work centres on Pharmaceuticals, Plant-inspired medicine, Global operations and Clinical development.

MGC Pharmaceuticals has approximately 37 employees.

MGC Pharmaceuticals has completed 5 funding rounds, raising a total of $20.70M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to MGC Pharmaceuticals include Kyowa Hakko USA, Laboratorios Ojer Pharma, Biota Laboratuvarları, Saudi Pharmaceutical Industries (SPI), Papaellinas Group. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

MGC Pharmaceuticals and Kyowa Hakko USA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About MGC Pharmaceuticals

Funding Rounds & Investors (5)

MGC Pharmaceuticals Alternatives & Competitors

FAQ About MGC Pharmaceuticals